Rankia Colombia Rankia Argentina Rankia Brasil Rankia Chile Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.260 / 16.979
#122074

Re: Farmas USA

  TG Therapeutics up 34% premarket on positive umbralisib data
• TG Therapeutics (NASDAQ:TGTX) announces positive topline results from a Phase 3 clinical trial, UNITY-CLL, comparing unbralisib plus ublituximab (U2) to obinutuzumab plus chlorambucil in patients with previously untreated relapsed/refractory chronic lymphocytic leukemia (CLL). 
• Based on a prespecified interim analysis by the independent Data Safety Monitoring Board, treatment with U2 resulted in a statistically significant improvement in progression-free survival (PFS). As a result, the study will be stopped early. 
• Management will host a conference call this morning at 8:30 am ET to discuss the results. 
• Shares up 34% premarket on modest volume.
#122075

Re: Farmas USA

Y esta tb la tengo, no se si alguien más
Adverum gene therapy shows positive action in wet AMD; shares up 22% premarket
• Adverum Biotechnologies (NASDAQ:ADVM) announces positive preliminary data from the first three cohorts in a Phase 1 dose-ranging clinical trial, OPTIC, evaluating gene therapy candidate ADVM-022, administered via intravitreal injection, in patients with wet age-related macular degeneration (wet AMD). 
• The company says ADVM-022 continues to show "robust" efficacy with long-durability of beyond a year from a single administration with no injections in cohort 1. 
• On the safety front, the gene therapy continues to be well-tolerated with a favorable safety profile. 
• Mean gain in best corrected visual acuity (BCVA) in cohort 3 was +6.8 letters. 
• It plans to file an IND for ADVM-022 in diabetic retinopathy (DR) this quarter. 
• Key H2 milestones: Present data from all four cohorts in OPTIC and launch enrollment in Phase 1/2 study of ADVM-022 in DR. 
• Shares up 22% premarket on modest volume.
#122079

Re: Farmas USA

AMRN
Compradas unas pocas a 7,71 hace un rato.
Por fin espabilan, parece.
Edito: Si quieren.
#122080

Re: Farmas USA

Amrn

Promierdaste al final?
Brokers destacados